Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension

Core Insights - Gossamer Bio, Inc. has announced an option agreement to acquire Respira Therapeutics and its lead product candidate RT234, which is an investigational inhaled vardenafil dry powder [1] Company Overview - Gossamer Bio is a late-stage clinical biopharmaceutical company focused on developing and commercializing seralutinib for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [1] Product Development - The acquisition of Respira Therapeutics will enhance Gossamer Bio's portfolio, particularly in the area of pulmonary hypertension treatments [1]